stars 1 stars 2 stars 3

View Permanova's top competitors like Adaptimmune, Apogenix GmbH, and Cytovation ASA.

Kite Pharma
At Kite, a Gilead Company, our singular focus is achieving cures with cell therapy. Our goal is to bring the promise of cell therapy to as many eligible patients as possible who may benefit. Since 2009, Kite has been at the forefront of cancer immunotherapy. Today, we are proud to be the leader in engineered T cell therapy for hematologic malignancies, but we recognize that this is just the beginning. Patients are at the heart of our focus on the cure, which is why we are committed to pursuing cell therapy as a transformative treatment option for as many patients as possible who may benefit. Unlike traditional pharmaceutical manufacturing, our therapies are not created on an assembly line. Cell therapy specialists at our manufacturing facilities reengineer a patient’s own immune cells to attack and fight their cancer cells — one patient at a time. That sense of connection to the people we serve motivates us daily at Kite. Our corporate headquarters are located in Santa Monica, California, and we have dedicated cell therapy manufacturing facilities in California, Maryland and the Netherlands. If you’re passionate about bringing the curative potential of cell therapy to more eligible patients, let’s talk. See our community guidelines: http://bit.ly/2DznMNw
Santa Monica, California, US
Public
$353.2M Revenue
http://www.kitepharma.com
4.1K Employees
NASDAQ:KITE Ticker
Genmab
We are an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. Long recognized for our expertise in antibody innovation, our passionate and collaborative team has pioneered antibody-based formats, including bispecific antibodies, antibody-drug conjugates, immune-modulating antibodies, and other modalities for the treatment of cancer and other serious diseases. Today, we are advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients. Our quest to turn science into medicine and transform the treatment of cancer and other serious diseases is guided by our core values: a passion for innovation, determination, integrity, working as one team, and respecting each other. When you work at Genmab you'll be part of a warm, fun, dynamic community seeking out and embracing the opportunity to build new and bold futures within a rapidly growing biotechnology company. Genmab is a place where you can be authentically you; you are empowered to innovate, build solutions and execute; you feel cared for and supported. Altogether, this makes working at Genmab an extra[not]ordinary® experience. Headquartered in Copenhagen, Denmark, Genmab has a strong international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com. Disclaimer: http://gmab.ly/Jn0e50XWplA
København V, DK
Public
$2.9B Revenue
http://www.genmab.com
3.1K Employees
GMAB Ticker
Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics (NASDAQ: IOVA) aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. We are adding to our talented team as we execute our commercial launch, advance our research and development efforts, and build our internal manufacturing capabilities. Iovance is headquartered in the San Francisco Bay Area. Our Iovance Cell Therapy Center (iCTC), a state-of-the-art manufacturing facility, is located in Philadelphia. We also have a research site in Tampa, Florida. Any information expressed by Iovance is subject to the risk factors and information on forward-looking statements contained in its filings with the Securities and Exchange Commission and available here: https://ir.iovance.com/sec-filings
Philadelphia, Pennsylvania, US
Public
$164.1M Revenue
http://www.iovance.com/
935 Employees
NASDAQ:IOVA Ticker
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users